Cellanyx is leveraging the unique capability to rapidly analyze live patient-biopsy-cells on an ex vivo platform powered by microfluidics, phenotypic biomarkers, machine vision, and machine learning.
Cellanyx's first-in-class platform is poised to dramatically disrupt the diagnostics and therapeutic tools markets that historically have been limited by static formalin-fixed cells, bulk and noisy genomic analysis, irrelevant cell line cultures and cumbersome animal models.
Ashok developed Cellanyx's core technology during an academic career researching topics including multidrug resistance and matrix-biology. A Fellow of Startup Leadership Boston, Ashok combines his background in biophysics with expertise in business on project management, operations, team development, entrepreneurship and raising capital.
Passionate about translating basic scientific discoveries into therapeutic gains, and engaged in oncology research since 1996, Ashok is exceptionally motivated to create meaningful value for patients, physicians, payers, and investors.
Ashok enjoys collaborating with executives, clinicians, engineers, and scientists to advance our understanding of biological processes, promote discovery, develop clinically actionable technologies, and create sustainable clinical and therapeutic value.
Ashok began his scientific training at the National Institutes of Health (NIH). Advised by two Nobel Laureates, Ashok received his S.B. in Biology from MIT and Ph.D. from Columbia University. Raised in Potomac, Maryland, Ashok is a lifelong tennis player and new father, appreciating their respective emphases on preparation, dedication, stamina, and good hands.